Gastroesophageal Cancer Clinical Trials

**Screening**

**Stage IV/Advanced**

- **UCI 16-77** Identification of Features Associated with Dysplasia Using the NvisionVLE Imaging System Pilot Trial (Chang)
- **UCI 16-99** Multi-center Study to Evaluate the C2 CryoBalloon Focal Ablation System for the Treatment of Patients with Previously-Uncured Dysplastic Barrett's Esophagus (Chang)

- **ECOG EAY131** Molecular Analysis for Therapy Choice (MATCH) (Bota)
- **SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)
- **UCI 16-96** A Phase I Study of the Highly-Selective RET Inhibitor, BLU-667, in Patients with Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors (Ou)
- **UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)

- **UCI 17-96** A Prospective Single Arm Multicenter Study Evaluating the Effects of Spray Cryotherapy in Patients with Persistent Local Esophageal Cancer (Samarasena)

**Correlative**

- **UCI 16-88** Development of Esophageal and Gastric Cancer Patient Derived Xenograft Mouse Models to Investigate Chemotherapy Resistance and Tumor Cell Response (Lyoo)
- **UCI 14-25** Plasma Exosome Concentration in Cancer Patients Undergoing Treatment (Nelson)
- **UCI 16-31** Importin α is a Novel Biomarker of Barrett’s Esophagus (BE)-Related Dysplasia & Cancer and Promotes Growth of BE-Derived Cancer Cells by Inducing Aberrant VEGF Expression (Samarasena)

**Supportive Care**

- **SWOG S1609** DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors (Bota)
- **UCI 17-50** A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects with Advanced Solid Tumors (Ou)
- **UCI 17-96** A Prospective Single Arm Multicenter Study Evaluating the Effects of Spray Cryotherapy in Patients with Persistent Local Esophageal Cancer (Samarasena)

For more details contact 1-877-UC-STUDY OR ucstudy@uci.edu

**Opening soon**